Giuseppe Curigliano, MD, PhD

Articles

Dr Curigliano on the Implications of T-DXd in HR+, HER2-Low and -Ultralow Breast Cancer

July 18th 2024

Giuseppe Curigliano, MD, PhD, discusses the implications of treatment with T-DXd in HR+, HER2-low or HER2-ultralow metastatic breast cancer.

Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

July 15th 2024

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

June 19th 2024

Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.

Addressing Treatment Gaps in HER2+ MBC

December 13th 2021

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Optimizing Therapy in HER2+ MBC Across the Globe

December 13th 2021

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

Therapeutic Sequencing in HER2+ MBC

December 13th 2021

A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.

Updates to HER2CLIMB in HER2+ MBC

November 29th 2021

Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.

Managing TRAEs Associated With Novel HER2+ MBC Therapies

November 22nd 2021

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Updated Data From DESTINY-Breast03 in HER2+ MBC

November 15th 2021

Practice-changing data from the DESTINY-Breast03 trial evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer presented at ESMO 2021.

Standard Treatment Approaches in HER2+ MBC

November 8th 2021

A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.

Global Trends in HER2+ MBC

November 8th 2021

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th 2021

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.

Future Opportunities With Novel Therapies for HER2+ Breast Cancer

September 8th 2021

Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.

R/R Metastatic HER2+ Breast Cancer Treatment Considerations

September 8th 2021

Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.

HER2+ Breast Cancer: Key Takeaways From HER2CLIMB

September 8th 2021

An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.

Standard of Care for R/R Metastatic HER2+ Breast Cancer

September 8th 2021

Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.

Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer

May 31st 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.